Concurrent whole brain radiotherapy and short-course chloroquine in patients with brain metastases: A pilot trial

Journal of Radiation Oncology

Volumn 2, Issue 3, 2013, Pages 315-321

  Eldredge, Harriet B ^a,c   DeNittis, Albert ^a   DuHadaway, James B ^a   Chernick, Michael ^a   Metz, Richard ^b   Prendergast, George C ^a,c  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b Lankenau Institute for Medical Research ^*  (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Brain metastases; Chloroquine; Immunomodulation; Immunotherapy; Indoleamine 2,3 dioxygenase (Ido); Non small cell lung cancer (Nsclc); Whole brain radiotherapy

Indexed keywords

CHLOROQUINE; INDOLEAMINE 2, 3 DIOXYGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ARTICLE; BRAIN METASTASIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; DNA SEQUENCE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENOTYPING TECHNIQUE; GLIOMA; HUMAN; MALE; MEDICAL PROCEDURES; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PILOT STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DERMATITIS; RADIATION DOSE; WHOLE BRAIN RADIOTHERAPY;

EID: 84907922428     PISSN: 19487894     EISSN: 19487908     Source Type: Journal    
DOI: 10.1007/s13566-013-0111-x     Document Type: Article

References (39)

1. Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75(1): 5-14.
2. Delattre JY et al (1988) Distribution of brain metastases. Arch Neurol 45(7): 741-744.
3. Nussbaum ES et al (1996) Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 78(8): 1781-1788.
4. Posner JB (1978) Neurologic complications of systemic cancer. Dis Mon 25(2): 1-60.
5. Videtic GM et al (2009) American College of Radiology appropriateness criteria on multiple brain metastases. Int J Radiat Oncol Biol Phys 75(4): 961-965.
6. Lagerwaard FJ et al (1999) Identification of prognostic factors in patients with brain metastases: a review of 1, 292 patients. Int J Radiat Oncol Biol Phys 43(4): 795-803.
7. Lutterbach J, Bartelt S, Ostertag C (2002) Long-term survival in patients with brain metastases. J Cancer Res Clin Oncol 128(8): 417-425.
8. Gaspar L et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4): 745-751.
9. Sperduto CM et al (2008) A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment. J Neurosurg 109(Suppl): 87-89.
10. Sperduto PW et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4, 259 patients. Int J Radiat Oncol Biol Phys 77(3): 655-661.
11. Kim EL et al (2010) Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro Oncol 12(4): 389-400.
12. Briceno E, Calderon A, Sotelo J (2007) Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol 67(4): 388-391.
13. Sotelo J, Briceno E, Lopez-Gonzalez MA (2006) Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144(5): 337-343.
14. Hou DY et al (2007) Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67(2): 792-801.
15. Metz R et al (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor IDO inhibitory compound D-1MT. Cancer Res 67: 7082-7087.
16. Katz JB et al (2008) Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 222: 206-221.
17. Munn DH, Mellor AL (2007) Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest 117(5): 1147-1154.
18. Smith C et al (2012) IDO Is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2(8): 722-735.
19. Andrews DW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363(9422): 1665-1672.
20. Kondziolka D et al (1999) Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45(2): 427-434.
21. Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer 45(2): 228-247.
22. Ben-Zvi I et al (2012) Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 42(2): 145-153.
23. Munshi A et al (2008) Unusual intensification of skin reactions by chloroquine use during breast radiotherapy. Acta Oncol 47(2): 318-319.
24. Rustogi A, Munshi A, Jalali R (2006) Unexpected skin reaction induced by radiotherapy after chloroquine use. Lancet Oncol 7(7): 608-609.
25. Borgelt B et al (1981) Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7(12): 1633-1638.
26. Davey P et al (2008) A phase III study of accelerated versus conventional hypofractionated whole brain irradiation in patients of good performance status with brain metastases not suitable for surgical excision. Radiother Oncol 88(2): 173-176.
27. Haie-Meder C et al (1993) Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother Oncol 26(2): 111-116.
28. Murray KJ et al (1997) A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 39(3): 571-574.
29. Antonadou D et al (2002) Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20(17): 3644-3650.
30. DeAngelis LM et al (1989) The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J Neurooncol 7(3): 241-247.
31. Eyre HJ et al (1984) Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain. A Southwest Oncology Group study J Neurooncol 2(4): 325-330.
32. Komarnicky LT et al (1991) A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 20(1): 53-58.
33. Phillips TL et al (1995) Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 33(2): 339-348.
34. Mehta MP et al (2009) Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 73(4): 1069-1076.
35. Scott C et al (2007) Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am J Clin Oncol 30(6): 580-587.
36. Suh JH et al (2006) Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 24(1): 106-114.
37. Jensen PB, Sehested M (1997) DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol 54(7): 755-759.
38. Sorensen M, Sehested M, Jensen PB (1997) pH-dependent regulation of camptothecin-induced cytotoxicity and cleavable complex formation by the antimalarial agent chloroquine. Biochem Pharmacol 54(3): 373-380.
39. Amaravadi RK et al (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17(4): 654-666.